World AI Cannes Festival: must-see speakers in 2023
24.1.2023 11:25:00 EET | Business Wire | Press release
The World AI Cannes Festival will take place in Cannes on February 9, 10 and 11 2023. This is the top world event dedicated exclusively to AI, tech leaders innovating in AI and the economic, human and societal issues that will impact our lives in the short term.
The event is a chance to get up to speed on the current marketplace, learn from the best experts and to meet decision-makers and top business leaders. Many notable speakers will deliver presentations and lead strategic conferences, think-tank workshops, exhibition stands and networking sessions.
Spotlight on the major speakers for 2023
The WAICF is an opportunity for artificial intelligence professionals and experts , whether from professional backgrounds, research or public administrations, to meet and exchange views on developments in the sector.
The 100+ international speakers at the WAICF in 2023 will include:
- Yann Lecun, Vice-President and Chief AI Scientist, Meta AI
- Joann Stonier, Chief Data Officer, Mastercard
- Wolfgang Hauner, Head of Group Data Analytics, Allianz
- Saeed Contractor, Global Head of Intelligent Automation COE, Uber
- Manuela M. Veloso, Head, J. P. Morgan Chase AI Research
- Xavier Lagardere, Chief Data Officer, Vice President Data Strategy and Transformation, Lufthansa Group
- Stuart Russell, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, University of California, Berkeley
- Alberto Prado, Vice-President, Global Head of R&D Digital & Partnerships, Unilever
- Divya Dwivedi, Advocate, Supreme Court of India
- Aidan Gomez, Co-Founder and CEO, Cohere
- Thomas Wolf, Co-Founder and Chief Science Officer, Hugging Face
- John Kamara, Founder and CEO/founder, Adanian Labs/AI Center of Excellence (AICE)
- Michael Kearns, Amazon Scholar, University of Pennsylvania
- Michaela Schutt, SVP, Head of Global Talent Acquisition Ecosystem, Siemens
- Nozha Boujemaa, Global VP - Digital Ethics and Responsible AI, IKEA Retail
- Oren Etzioni, CEO, Allen Institute for AI
The Festival will provide an overview of AI in all its diversity through 5 key conference tracks:
- AI FOR SOCIETY: Understand the benefits of AI for society and our planet, and the challenges that must be met.
- AI TODAY AND TOMORROW: Explore what AI can do today, and picture what future innovations will offer tomorrow's society and organizations.
- AI STRATEGY: Get key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: Learn how best to use the different AI technologies, and shape your innovation mindset with top-level speakers.
- AI APPLICATIONS: Get an overview of the advances organizations can make using AI, through focuses on various industries.
Full list of conferences and speakers
Get accreditation through the media pass site
About World AI Cannes Festival
The World AI Cannes Festival brings together industry experts, professionals, and the general public to attend exhibitions, workshops, happenings, conferences, networking and meet-ups with an international dimension. The rich and varied program highlights the latest AI applications in business and in everyday life. A unique opportunity for national and international institutions, associations, businesses and start-ups across the world to meet their target audiences, highlight their expertise and demonstrate their commitment to ethical and sustainable AI.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005541/en/
Contact information
Press contacts WAICF 2023
Profile Agency –
waicf@agence-profile.com
Jennifer Loison – 06 10 22 52 37 | Shérazade El Houari – 06 22 35 69 79
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom